A clinical-stage biotechnology company in Immuno-Oncology and Immuno-Inflammation

Focused on developing and partnering therapies to control the immune system for Immuno-Oncology and Immuno-Inflammation.

Our latest press release

Read more

27/03/2024

OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update

Download

To receive OSE Immunotherapeutics’ latest news